New Clamping System for Mobetron IntraOp Medical

Document Sample
New Clamping System for Mobetron IntraOp Medical Powered By Docstoc
					                                MOBETRONNEWS
October 2012, First Issue




                                Here Herr Professor
                                Audretsch while
                                placing the applicator
                                in an easy and fast
                                way



                                     New Clamping System for Mobetron
                                       It	
   has	
   recently	
   been	
   developed	
   a	
   new	
   Clamping	
  
                            System	
  for	
  applicators	
  in	
  the	
  clinical	
  use.
                                       This	
   new	
   system	
   combines	
   the	
   utility	
   of	
   the	
  
                            Unitrac	
   Arm	
  with	
   the	
  Mobetron	
  applicators	
  to	
   allow	
  users	
  
                            to	
  place	
  the	
  applicator	
  in	
   a	
   faster	
  and	
  more	
  precise	
  way	
  on	
  
                            the	
  treatment	
  area.
                                       Once	
   the	
   arm	
   has	
   been	
   placed	
   on	
   the	
   area,	
   by	
  
                            releasing	
  the	
  security	
  valve,	
  it	
  remains	
  Aixed	
  in	
  the	
  proper	
  
                            position.
                                       This	
  operation	
  takes	
  maximum	
  10	
  seconds,	
  and	
  the	
  
                            applicator	
  is	
  safely	
  and	
  Airmly	
  placed.
                                       This	
  development	
  has	
  been	
  inspired	
  and	
  suggested	
  
                            by	
   Professor	
   Audretsch	
   from	
   Marien	
   Hospital	
   in	
  
                            Dusseldorf,	
  Germany.
                                         Please	
  refer	
  to	
  info@md51.com	
  for	
  more	
  info.


                             MobetronNews.
                             With this first Issue of of periodical news bulletin, we are trying to start informing our
                             Users and our Friends, on the latest development of our community, and try to create
                             a bundle that could lead to succesfull and usefull experiences.
                             We hope, with this to also create a connection between the company and our Users to
                             bring more new ideas on how to better develop the Mobetron and create new tools for
                             better use the unit. We hope you appreciate it.
                             	     	     	     	      	     	    	     	     	     Ernesto G. Lanzotti CEO MD51

                            1
                             Dr. Jay Harness Presented Verona’s Breast Study at ASCO
                             BC 2012 in San Francisco
MOBETRONNEWS, OCTOBER 2012


                             ABPI Using a Single Dose of IOERT. Safe, Effective in Low Risk Early Breast Cancer


                                 At	
   ASCO	
   BCS	
   2012	
   held	
   in	
   San	
   Francisco	
   last	
  
                                 September	
  12-­‐13.
                                 A	
   prospective	
   phase	
   II	
   trial	
   of	
   single-­‐dose	
   IOERT	
  
                                 recently	
   conducted	
   in	
   226	
   women	
   with	
   low-­‐risk,	
  
                                 early-­‐stage	
   breast	
   cancer	
   who	
   were	
   treated	
   with	
  
                                 wide	
   local	
  excision	
   (quadrantectomy)	
  and	
   axillary	
  
                                 management	
   identiAied	
   only	
   one	
   case	
   of	
   local	
  
                                 recurrence	
  (0.4%)	
  during	
   a	
   median	
   follow	
  up	
  of	
   49	
  
                                 months	
   (range:	
   31	
   to	
   66	
   months).	
   The	
   annual	
  
                                 recurrence	
  rate	
  was	
  approximately	
  0.2%
                                 "Patients	
  at	
  very	
  low	
  risk	
  of	
   local	
  recurrence,	
  such	
  
                                 as	
  patients	
  deemed	
   suitable	
  for	
  APBI	
  [according	
  to	
  
                                 American	
   Society	
   for	
   Radiation	
   Oncology	
   and	
  
                                 European	
   Society	
   for	
   Radiotherapy	
   &	
   Oncology	
  
                                 guidelines],	
  represent	
  an	
  excellent	
  group	
   to	
   receive	
  
                                 this	
   one-­‐dose	
   procedure,	
   [avoiding]	
   the	
   5	
   to	
   6	
  
                                 weeks	
   of	
   postoperative	
   treatment,"	
   said	
   Jay	
   K.	
  
                                 Harness,	
   MD,	
   FACS,	
   of	
   St.	
   Joseph	
   Hospital	
   in	
  
                                 California.
                                 The	
  Verona	
  investigators	
  identiAied	
  no	
  discernible	
  
                                 increase	
  in	
  edema,	
  discoloration,	
  dimpling,	
  or	
  
                                 scarring	
  following	
  single-­‐dose	
  IOERT.	
  In	
  fact,	
  
                                 asymmetry	
  was	
  the	
  only	
  cosmetic	
  complication	
                         "Single-­‐dose	
   IOERT	
   in	
   early-­‐stage	
   breast	
  cancer	
   can	
  
                                 associated	
  with	
  the	
  procedure,	
  with	
  7.5%	
  of	
                       be	
   delivered	
   safely	
   and	
   with	
   excellent	
   results—and	
  
                                 patients	
  experiencing	
  grade	
  3	
  asymmetry	
  that	
                         here’s	
   the	
  caveat—in	
   properly	
  selected	
   patients,"	
   Dr.	
  
                                 involved	
  more	
  than	
  one-­‐third	
  of	
  the	
  gland.	
  Dr.	
               Harness	
   concluded.	
   "Despite	
   these	
   encouraging	
  
                                 Harness	
  commented	
  that	
  this	
  asymmetry	
  may	
  be	
                      results,	
   clearly	
  longer	
  follow-­‐up	
  is	
  needed	
  to	
   compare	
  
                                 due	
  more	
  to	
  the	
  surgical	
  procedure—                                    IOERT	
   APBI	
   efAicacy	
   to	
   that	
   of	
   whole-­‐breast	
  
                                 quadrantectomy—than	
  to	
  IOERT.                                                   irradiation."


                                         	
  Check	
  the	
  MD51	
  youtube	
  channel	
  for	
  reviewing	
  this	
  presentation:	
  http://www.youtube.com/user/md51srl


                                 A new type of Bolus is being tested. Soon a paper from Trieste.

                                    Here the new
                                    bolus that is
                                    currently being
                                    tested from the
                                    University of
                                    Trieste. This
                                    type of bolus
                                    has been
                                    created to
                                    eliminate the
                                    back scatter
                                    radiation and it
                                    consists of a
                                    10mm bolus
                                    with inserted,
                                    asymmetrically,
                                    a 3 mm copper
                                    disc.


                             2

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:6
posted:12/13/2012
language:English
pages:2